The new European regulation on pediatric medicines: Safety and ethics perspectives

Pediatric Drugs

Volumn 10, Issue 3, 2008, Pages 147-149

  Neubert, Antje ^a   Planner, Claire ^a   Cranswick, Noel ^b  

^a UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

Children; Ethics; Pharmacovigilance; Regulatory process

Indexed keywords

CHILD; DECISION MAKING; DRUG RESEARCH; DRUG SURVEILLANCE PROGRAM; EDITORIAL; ETHICS; EUROPEAN UNION; HUMAN; LAW; PRIORITY JOURNAL; RISK MANAGEMENT; SAFETY;

CHILD; CLINICAL TRIALS AS TOPIC; EUROPEAN UNION; HUMANS; LEGISLATION, DRUG; PEDIATRICS; PHARMACEUTICAL PREPARATIONS; QUALITY ASSURANCE, HEALTH CARE;

EID: 43049095354     PISSN: 11745878     EISSN: None     Source Type: Journal    
DOI: 10.2165/00148581-200810030-00003     Document Type: Editorial

References (23)

1. Conroy S, Choonara I, Impicciatore P, et al. Survey of unlicensed and off-label drug use in pediatric wards in European countries: European Network for Drug Investigation in Children. BMJ 2000; 320 (7227): 79-82
2. Neubert A, Dormann H, Weiss J, et al. The impact of unlicensed and off-label drug use on adverse drug reactions in pediatric patients. Drug Saf 2004; 27 (13): 1059-67
3. Wong IC, Basra N, Yeung VW, et al. Supply problems of unlicensed and off-label medicines after discharge. Arch Dis Child 2006; 91 (8): 686-8
4. European Commission. Regulation (EC) No 1901/2006 of the European Parliament and of the Council on medicinal products for pediatric use 2006 [online]. Available from URL: http://eur-lex.europa.eu/LexUriServ/site/en/oj/ 2006/l_378/l_37820061227en00010019.pdf [Accessed 2007 Sep 9]
5. Directive 2001/20/EC of the European Parliament and of the Council on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use 2001/20/EC, 4 April 2001. Official Journal of the European Communities 2001; (L121): 34-44
6. Ford K, Sankey J, Crisp J. Development of children's assent documents using a child-centered approach. J Child Health Care 2007; 11 (1): 19-28
7. Dorn LD, Susman EJ, Fletcher JC. Informed consent in children and adolescents: age, maturation, and psychological state. J Adolesc Health 1995; 16 (3): 185-90
8. Kuther TL, Posada M. Children and adolescents' capacity to provide informed consent for participation in research. Adv Psychol Res 2004; 32: 163-73
9. Bergler JH, Pennington AC, Metcalfe M, et al. Informed consent: how much does the patient understand? Clin Pharmacol Ther 1980; 27 (4): 435-40
10. Byrne DJ, Napier A, Cuschieri A. How informed is signed consent? Br Med J (Clin Res Ed) 1988; 296 (6625): 839-40
11. Rossi WC, Reynolds W, Nelson RM. Child assent and parental permission in pediatric research. Theor Med Bioeth 2003; 24 (2): 131-48
12. Lynoe N, Sandlund M, Dahlqvist G, et al. Informed consent: study of quality of information given to participants in a clinical trial. BMJ 1991; 303 (6803): 610-3
13. Committee for Medicinal Products for Human Use (CHMP). Guidelines on conduct of pharmacovigilance for medicines used by the paediatric population [online]. Available from URL: http://www.emea.eu.int/pdfs/human/phvwp/ 23591005en.pdf: [Accessed 2007 Mar 10]
14. US FDA. Drugs to which FDA has granted pediatric exclusivity for pediatric studies under Section 505A of the Federal Food, Drug, and Cosmetic Act [online]. Available from URL: http://www.fda.gov/cder/pediatric/exgrant.htm. [Accessed 2007 Oct 15]
15. US Food and Drug Administration. Pediatric exclusivity labeling changes as of August 8, 2007 [online]. Available from: URL: http://www.fda.gov/cder/ pediatric/labelchange.htm [Accessed 2007 Oct 15]
16. Grieve J, Tordoff J, Reith D, et al. Effect of the pediatric exclusivity provision on children's access to medicines. Br J Clin Pharmacol 2005; 59 (6): 730-5
17. European Medicine Agency, Pediatric needs, 1-7-2007 [online]. Available from URL: http://www.emea.europa.eu/htms/human/paediatrics/inventory.htm [Accessed 2008 Apr 3]
18. European Medicine Agency. Priority list of off-patent medicinal products for pediatric studies. EMEA [online]. Available from URL: http://www.emea. europa.eu/pdfs/human/peg/19797207en.pdf. [Accessed 2007 Sep 9]
19. Sturkenboom M, Verhamme K, Murray ML, et al. General drug utilization in children: a multinational database study in the TEDDY Project. Pharmacoepidemiol Drug Saf 2007; 16 Suppl. 2: S217-8
20. Ahmad OB, Lopez AD, Inoue M. The decline in child mortality: a reappraisal. Bull World Health Organ 2000; 78: 1175-91
21. World Health Organization. The world health report 2002: reducing the risks, promoting healthy life [online]. Available from URL: http://www.who.int/ whr/2002/en/whr02_en.pdf [Accessed 2008 Apr 3]
22. World Health Organization. Making medicines child size [online]. Available from: URL: http://www.who.int/childmedicines/en/. [Accessed 2007 Dec 6]
23. Shirkey H. Therapeutic orphans. J Pediatr 1968; 1962 (72): 119-20